Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Solid Tumors”

603 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 603 results

Early research (Phase 1)Looking for participantsNCT05857332
What this trial is testing

SG1906 for CLDN18.2-Positive Solid Tumors

Who this might be right for
Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Early research (Phase 1)Study completedNCT04094506
What this trial is testing

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies
Astellas Pharma Inc 9
Early research (Phase 1)Looking for participantsNCT06349408
What this trial is testing

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 250
Testing effectiveness (Phase 2)UnknownNCT03961698
What this trial is testing

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Who this might be right for
Breast CancerRenal Cell Carcinoma
Infinity Pharmaceuticals, Inc. 91
Early research (Phase 1)Study completedNCT00504296
What this trial is testing

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
NCIC Clinical Trials Group 39
Early research (Phase 1)Ended earlyNCT06299761
What this trial is testing

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

Who this might be right for
Solid Tumor
Boundless Bio 19
Early research (Phase 1)Study completedNCT00968981
What this trial is testing

Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 67
Early research (Phase 1)Study completedNCT02650713
What this trial is testing

The Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

Who this might be right for
Solid Tumors
Hoffmann-La Roche 228
Testing effectiveness (Phase 2)Study completedNCT03543813
What this trial is testing

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Who this might be right for
Solid Tumor, AdultHead and Neck CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 133
Early research (Phase 1)Study completedNCT00550927
What this trial is testing

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Eli Lilly and Company 42
Early research (Phase 1)Study completedNCT01356173
What this trial is testing

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma, Solid Tumor
Genentech, Inc. 10
Early research (Phase 1)Looking for participantsNCT06908434
What this trial is testing

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Who this might be right for
Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd. 82
Early research (Phase 1)Study completedNCT03589651
What this trial is testing

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Who this might be right for
Unresectable or Metastatic Solid Tumors
Incyte Corporation 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Testing effectiveness (Phase 2)Ended earlyNCT05220098
What this trial is testing

First-in-Human Study of TAK-280 in Participants With Solid Tumors

Who this might be right for
Unresectable Locally Advanced or Metastatic Cancer
Takeda 69
Early research (Phase 1)Study completedNCT00927589
What this trial is testing

Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Who this might be right for
Solid Cancers
Genentech, Inc. 59
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Ended earlyNCT03573544
What this trial is testing

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Who this might be right for
Metastatic Solid TumorsLocally Advanced Solid Tumors
OBI Pharma, Inc 54
Early research (Phase 1)Study completedNCT01075464
What this trial is testing

The Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Cancers
Genentech, Inc. 64
Load More Results